Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing.
DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the 'Company' or 'Aytu') (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1.50. In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price.
The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company, before deducting underwriters' fees and other offering expenses, are expected to be approximately $14.4 million. The Company intends to use the net proceeds of this offering for general corporate purposes, working capital and general and administrative expenses, and to execute on a transaction that will enable the Company to exclusively commercialize EXXUA™ (gepirone) extended-release tablets, a novel, branded, FDA-approved treatment for major depressive disorder in the United States.
Lake Street Capital Markets, LLC is acting as sole book runner in connection with the offering. Maxim Group LLC is acting as lead manager, and Ascendiant Capital Markets, LLC is acting as financial advisor.
The securities above are being offered pursuant to a registration statement on Form S-1, as amended, (File No. 333-287728) which was declared effective by the United States Securities and Exchange Commission (the 'SEC') on June 5, 2025, and registration statement on Form S-1MEF filed on June 6, 2025. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at https://www.sec.gov. The offering is being made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, when available, may also be obtained from Lake Street Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, Minnesota 55402, telephone: (612) 326-1305, or email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as 'anticipate,' 'believe,' 'expects,' 'intends,' 'may,' 'plan,' 'should,' 'subject to,' 'will,' 'would' or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding the timing and completion of the offering and the satisfaction of customary closing conditions related to the offering, the anticipated total gross proceeds from the offering and the planned use of the net proceeds of the offering, including those received from the exercise of the underwriters' option, if any. For such statements, Aytu claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Aytu's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Aytu's filings with the SEC, including its Annual Report on Form 10-K filed on September 26, 2024, and its Quarterly Reports on Form 10-Q. These forward-looking statements represent Aytu's judgment as of the time of this release. Aytu disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum or Roger Weiss
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
24 minutes ago
- Associated Press
NBA's talks about new league in Europe are continuing, though the process remains in early stages
OKLAHOMA CITY (AP) — The NBA's talks with FIBA and other entities about the process of adding a new league in Europe are continuing, Commissioner Adam Silver said, though he noted that it may take at least a couple more years to turn the ideas into reality. Silver spoke at a league event to unveil a refurbished Boys & Girls Club in Oklahoma City on Friday — an off day for the NBA Finals — and said it's difficult to put a specific timeline on the Europe plans. 'I will say it's measured in years, not months,' Silver said. 'So, we're at least a couple years away from launching. It would be an enormous undertaking. And while we want to move forward at a deliberate pace, we also want to make sure that we're consulting with all the appropriate stakeholders, meaning the existing league, its teams, European players, media companies, marketing partners. There's a lot of work to be done.' Silver and FIBA secretary general Andreas Zagklis announced in March that the league and the game's governing body are finally taking long-awaited steps to form a new league, with an initial target of 16 teams. It had been talked about for years, and decades even on some levels. And since the NBA and FIBA went public with their idea to move forward, talks have gotten more constructive, Silver said. Silver said the NBA has been talking directly with the EuroLeague and with some member clubs about a partnership. It's his preference that the NBA work with the existing league on some level, though it's still too early to say exactly what that means. 'Either way, we continue to feel there are an enormous number of underserved basketball fans in Europe and that there's a strong opportunity to have another league styled after the NBA,' Silver said. About one in every six current NBA players hails from Europe, including Denver's Nikola Jokic (Serbia) and Milwaukee's Giannis Antetokounmpo (Greece) — who have combined for five of the last seven MVP awards — along with the Los Angeles Lakers' Luka Doncic (Slovenia) and San Antonio's Victor Wembanyama (France). The NBA's board of governors will talk more about next steps with the European plans in July at their scheduled meeting in Las Vegas, Silver said. It's possible that the European venture could be unveiled in some way — or possibly start — around the 2028 Los Angeles Olympics, just given how much attention will be on international basketball at that time. 'That might be a good launching pad for an announcement around a new competition,' Silver said. Some of the cities that are expected to have interest in being part of the new venture include London, Manchester, Rome and Munich. There will be others, of course. 'We haven't had direct conversations yet,' Silver said. 'But there have been several organizations that have come forward and said they would be interested and potential owners in operating in those major markets in Europe.' ___ AP NBA:
TechCrunch
28 minutes ago
- TechCrunch
Trump fast-tracks supersonic travel, amid spate of flight-related executive orders
In Brief President Donald Trump signed an executive order Friday that directs the Federal Aviation Administration to lift the 52-year ban on supersonic flight over U.S. soil, marking a major policy shift that occurred just weeks after lawmakers introduced bipartisan legislation with the same aim. The order instructs the FAA to end the overland supersonic ban and create noise-based certification standards, allowing faster-than-sound travel as long as no audible sonic boom reaches the ground. 'The reality is that Americans should be able to fly from New York to LA in under four hours,' Michael Kratsios, the director of the White House Office of Science and Technology Policy, told reporters Friday. The move could help accelerate commercial supersonic flight development, including efforts by Boom Supersonic. In January, Boom's XB-1 demonstrator became the first privately developed civil aircraft to break the sound barrier over the continental U.S. Asked for comment Friday, Boom CEO Blake Scholl wrote 'Booooom!' in an email to TechCrunch. Added Scholl, 'The sound barrier was never physical — it was regulatory. With supersonic legalized, the return of supersonic passenger air travel is just a matter of time.' Trump also signed two other future-of-flight executive orders Friday: one to speed up drone commercialization and electric vertical takeoff vehicle development, and another to establish a federal task force on drone flight restrictions.
Wall Street Journal
41 minutes ago
- Wall Street Journal
The Republican at the Center of the War Between Trump and Musk
Caught in the middle of President Trump and billionaire Elon Musk's spectacular fallout is a Republican operative with close ties to both men. Katie Miller, 33, is a former Trump White House staffer married to White House deputy chief of staff Stephen Miller. Over the last year, she became a top adviser to Musk and worked at his side as he slashed and reshaped the federal government from his position as the leader of the Department of Government Efficiency.
